Genentech has announced positive results from its primary analysis of an ongoing study assessing safety and efficacy of Evrysdi in babies with pre-symptomatic spinal muscular atrophy.
Data from the RAINBOWFISH study were presented at the 28th World Muscle Society Congress, held from Oct. 3 to Oct.7 in South Carolina.
